Alzamend Neuro Inc(ALZN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 30 at 5:33 PM ET (Korea 10/1 06:33)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.29 | Insider Own | 2.66% | Shs Outstand | 4.8M | Perf Week | -10.82% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 17.14% | Insider Trans | 483.6% | Shs Float | 4.7M | Perf Month | 8.12% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -0.56 | Inst Own | 28.81% | Short Float | 2.62% | Perf Quarter | 54.46% |
| Income | -0.01B | P/S | - | EPS this Y | 60.08% | Inst Trans | 17.22% | Short Ratio | 0.75 | Perf Half Y | 63.21% |
| Sales | 0.00B | P/B | 1.44 | EPS next 5Y | - | ROA | -122.36% | Short Interest | 0.12M | Perf YTD | -4.95% |
| Book/sh | 1.2 | P/C | 1.1 | EPS past 3/5Y | 76.63% 51.15% | ROE | -163.23% | 52W High | -35.45% ($2.68) | Perf Year | -27.31% |
| Cash/sh | 1.57 | P/FCF | - | Sales past 3/5Y | - | ROIC | -156.77% | 52W Low | 105.95% ($0.84) | Perf 3Y | -99.46% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 73.61% | Gross Margin | - | Volatility(W/M) | 6.43% 5.46% | Perf 5Y | -99.96% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.1 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.01 | EPS Q/Q | 47.33% | Profit Margin | - | RSI (14) | 49.65 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.01 | Sales Q/Q | - | SMA20 | -3.03% ($1.78) | Beta | 0.27 | Target Price | $26 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/07/01 | SMA50 | 8.38% ($1.6) | Rel Volume | 0.13 | Prev Close | $1.82 |
| Employees | 6 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -7.46% - | SMA200 | 10.23% ($1.57) | Avg Volume(3M) | 0.16M | Price | $1.73 |
| IPO | 2021/6/15 | Option/Short | No/Yes | Trades | 142 | Volume | 21,350 | Change | -4.95% |
🧠 This is a US micro-cap clinical-stage biotech developing therapeutics for brain and neurological disorders such as Alzheimer's disease, bipolar disorder, depression, and post-traumatic stress disorder (PTSD). Its key candidates are AL001, which delivers lithium in a novel crystalline form, and ALZN002, an immunotherapy targeting beta-amyloid.
Over the past 1 year, roughly in the middle
35% below its 1-year high.
Traded less than usual That is 13% of its average volume.
ALZN has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +60.1% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +78% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 28.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #523 of 592 in the industry
Based on market cap of $8M.
LGVN#521 Longeveron Inc $9M PER - 
NRSN#522 NeuroSense Therapeutics Ltd $8M PER - ALZN#523 Alzamend Neuro Inc $8M PER - 
AZTR#524 Azitra Inc $8M PER - 
KALA#525 Kala Bio Inc $8M PER - 
FAQ
What kind of company is ALZN?
ALZN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ALZN?
The market cap of ALZN is approximately $8M, ranking 5,543 within its sector.
What is the 52-week high and low for ALZN?
ALZN has recorded a 52-week high of $2.68 and a low of $0.84.
